Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway

Table 5

Cost-effectiveness of etoricoxib relative to other interventions (base-case scenario).

	Incremental costs in NOK			Incremental QALYs			Incremental cost-effectiveness ratio
	Estimate	95% CrI		Estimate	95% CrI		Estimate	95% CrI
1 year
Etoricoxib (90 mg) versus celecoxib (200 & 400 mg)	−337	−411	−280	0.06	0.03	0.10	Dominant	Dominant	Dominant
Etoricoxib (90 mg) versus diclofenac	2,964	2,753	3,173	0.05	0.02	0.09	59,221	33,180	184,500
Etoricoxib (90 mg) versus naproxen	3,666	3,109	4,046	0.03	0.01	0.07	107,256	51,320	494,300
5 years
Etoricoxib (90 mg) versus celecoxib (200 & 400 mg)	−24,730	−37,730	−11,720	0.20	0.08	0.33	Dominant	Dominant	Dominant
Etoricoxib (90 mg) versus diclofenac	−10,320	−26,070	2,840	0.17	0.05	0.30	Dominant	Dominant	Dominant
Etoricoxib (90 mg) versus naproxen	−7,682	−23,540	5,729	0.12	0.02	0.23	Dominant	Dominant	Dominant
30 years
Etoricoxib (90 mg) versus celecoxib (200 & 400 mg)	−109,400	−198,700	−38,640	0.51	0.25	0.84	Dominant	Dominant	Dominant
Etoricoxib (90 mg) versus diclofenac	−80,060	−164,800	−13,280	0.45	0.20	0.76	Dominant	Dominant	Dominant
Etoricoxib (90 mg) versus naproxen	−76,850	−162,100	−9,622	0.36	0.13	0.66	Dominant	Dominant	Dominant